
BENZONATATE - benzonatate capsule, liquid filled RedPharm Drug Inc.

Benzonatate Capsules, USP 100 mg and 200 mg

Rx only

DESCRIPTION

Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.



C30H53NO11

Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP.

Benzonatate Capsules also contain: D and C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium.

CLINICAL PHARMACOLOGY

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

INDICATIONS AND USAGE

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

CONTRAINDICATIONS

Hypersensitivity to benzonatate or related compounds.

WARNINGS

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule

instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

PRECAUTIONS

Benzonatate is chemically related to anesthetic agents of the para-aminobenzoic acid class (e.g., procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Information for the Patient

Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. Therefore, the capsules should be swallowed without chewing.

Usage in Pregnancy:

Pregnancy Category C.

Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzonatate is administered to a nursing woman.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.

Pediatric Use:

Safety and effectiveness in children below the age of 10 has not been established.

ADVERSE REACTIONS

Potential Adverse Reactions to benzonatate may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.

GI: constipation, nausea, GI upset.

Dermatologic: pruritus; skin eruptions.

Other: nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity.

Rare instances of deliberate or accidental overdose have resulted in death.

OVERDOSAGE

Overdose may result in death.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms:

If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly. CNS stimulation may cause restlessness and tremors, which may proceed to clonic convulsions followed by profound CNS depression.

Treatment:

Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the

conscious patient, cough and gag refluxes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturates given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

DOSAGE AND ADMINISTRATION

Adults and children over 10:

Usual dose is one 100 mg or 200 mg capsules t.i.d. as required. If necessary, up to 600 mg daily may be given.

HOW SUPPLIED

Benzonatate Capsules, USP are available as:

Soft gelatin capsules, 100 mg (oval, yellow); bottle of 100

Imprint: A1.

NDC# 65162-536-10

Soft gelatin capsules, 100 mg (oval, yellow); bottle of 500

Imprint: A1.

NDC# 65162-536-50

Soft gelatin capsules, 200 mg (oblong, yellow); bottle of 100

Imprint: A2.

NDC# 65162-537-10

Store at 25°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP.

Manufactured by: Swiss Caps AG

Hausenstrasse 35

CH-9533, Kirchberg, Switzerland

Distributed by:

Amneal Pharmaceuticals

Glasgow, KY 42141

Rev. 09-2008

copy of label

Rx Only		NDC: 67296- BENZON 100MG 15 Capsu	ATATE		05671 6
	Lot:	369008 1	Exp: 04/11		
	Sector 1	Contraction of the second second			
Usual adult dosa Store at controlle	ge: See	package insert	5 C (68-77 F)		296
Store at controlle Mfg. by: Swi	ge: See ed room te ss Caps / thberg, Sv	package insert emperature: 20-2	5 C (68-77 F)	LCN: 35479	67296

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67296-0567C NDC:67296-0567C Product Type ORAL ORAL NDC:67296-0567C NDC:67296-0567C NDC:67296-0567C Route of Administration ORAL NDC:67296-0567C NDC:67296-0567C NDC:67296-0567C Route of Administration ORAL NDC:67296-0567C NDC:67296-0567C NDC:67296-0567C Route of Administration ORAL NDC:67296-0567- NDC:67296-0567- NDC:67296-0567- Route of Administration ORAL NDC:67296-0567- NDC:67296-0567- NDC:67296-0567- NDC:67296-0567- Its in 1B UTLE NDC:67296-0567- NDC:67296-0567- NDC:67296-0567-	BENZONAT	ATE									
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67296-0567(NDC:65162-52 Route of Administration ORAL Marketing Editent/Active Moiety Basis of Strength Strength Strength Basis of Strength Strength Basis of Strength Strength Basis of Strength Strength Basis of Strength Strength Basis of Strength Strength Dac Yellow No. 10 (UNIE 355W5USQ3G) Strength glatin (UNIE 2686QN327L) glatin (UNIE 2686QN327L) glatin (UNIE 2686QN327L) glatin (UNIE 2686QN327L) Score no score Shape OVAL (Soft Gelatin Capsules) Size 9mm Flavor Imprint Code A 1 Colatins Packaging # Marketing End Date <th></th> <th></th> <th>d filled</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>			d filled								
Product Type HUMAN PRESCRIPTION DRUG Net:											
ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BENZONATATE (UNIE 5P4DH56ENR) (BENZONATATE - UNIE5P4DH56ENR) BENZONATATE 100 mg Ingredient Name Strength D&C Yellow No. 10 (UNIE 35W5USQ3G) Strength glatin (UNIE 266QN327L) Strength glatin (UNIE 266QN327L) Strength glatin (UNIE CR6K9C2NHK) Strength glatin (UNIE 625NNB0G9N) Store Store Product Characteristics store Store Store Store Product Characteristics Inprint Code Store Store Product Characteristics Inprint Code Store Store OVAL (Soft Gelatin Capsules) Store Store Store Product Characteristics Inprint Code Store Store <th colspa<="" td=""><td>Product Infor</td><td>mation</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th>	<td>Product Infor</td> <td>mation</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Product Infor	mation								
Active Ingredient/Active Moiety Basis of Strength Strength BENZONATATE (UNIE SP4DHSGENR) (BENZONATATE - UNIESP4DHSGENR) BENZONATATE 100 mg BENZONATATE (UNIE SP4DHSGENR) (BENZONATATE - UNIESP4DHSGENR) BENZONATATE 100 mg Inactive Ingredient Name Strength D&C Yellow No. 10 (UNIE 3SW5USQ3G) Strength gelatin (UNIE 2G66QN327L) Strength gelatin (UNIE 2G66QN327L) Strength gelatin (UNIE CR6K9C2NEK) Strength Strength Sodium (UNIE CR6K9C2NEK) Strength Store Store Store <th>Product T ype</th> <th></th> <th></th> <th>HUMAN PRESCRIPTION</th> <th>N DRUG</th> <th>Ite m Coo</th> <th>de (Source</th> <th>e) NDC:672</th> <th>296-0562</th> <th>7(NDC:65162-5</th>	Product T ype			HUMAN PRESCRIPTION	N DRUG	Ite m Coo	de (Source	e) NDC:672	296-0562	7(NDC:65162-5	
Ingredient Name Basis of Strength Strength BENZONATATE (UNIE: SP4DHSGENR) (BENZONATATE - UNIE:SP4DHSGENR) BENZONATATE 100 mg Ingredient Name D&C Yellow No. 10 (UNIE: 35SW5USQ3G) glatin (UNIE: 2G86QN327L) Strength glatin (UNIE: 2G86QN327L) glatin (UNIE: 2G86QN327L) glatin (UNIE: 2G86QN327L) glycerin (UNIE: 2G86QOX) methylparaben sodium (UNIE: CR6K9C2NHK) proylparaben sodium (UNIE: 625NNB0G9N) Score NBOQVAL (Soft Gelatin Capsules) Size OVAL (Soft Gelatin Capsules) Imprint Code Imprint Code Size OVAL (Soft Gelatin Capsules) Size	Route of Adminis	stration		ORAL							
Ingredient Name Basis of Strength Strength BENZONATATE (UNIE: SP4DHSGENR) (BENZONATATE - UNIE:SP4DHSGENR) BENZONATATE 100 mg Inactive Ingredients Ingredient Name Strength D&C Yellow No. 10 (UNIE: 35SW5USQ3G) gelatin (UNIE: 2G8GQN327L) Strength gelatin (UNIE: 2G8GQN327L) Strength glycerin (UNIE: 2G8GQOX) Strength methylparaben sodium (UNIE: CR6K9C2NHK) Improve Improve Product Characteristics Improve Improve Imprint Code Imprint Code gelauin (UNIE: 625NNB0G9N) Size 9mm Imprint Code Imprint Code Imprint Code Size 9mm Flavor Imprint Code AI Size 9mm Flavor Imprint Code AI Product Character Imprint Code AI <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>											
Ingredient Name Basis of Strength Strength BENZONATATE (UNIE: SP4DHSGENR) (BENZONATATE - UNIE:SP4DHSGENR) BENZONATATE 100 mg Ingredient Name D&C Yellow No. 10 (UNIE: 35SW5USQ3G) glatin (UNIE: 2G86QN327L) Strength glatin (UNIE: 2G86QN327L) glatin (UNIE: 2G86QN327L) glatin (UNIE: 2G86QN327L) glycerin (UNIE: 2G86QOX) methylparaben sodium (UNIE: CR6K9C2NHK) proylparaben sodium (UNIE: 625NNB0G9N) Score NBOQVAL (Soft Gelatin Capsules) Size OVAL (Soft Gelatin Capsules) Imprint Code Imprint Code Size OVAL (Soft Gelatin Capsules) Size											
BENZONATATE (UNII: 5P4DH56ENR) (BENZONATATE - UNIE5P4DH56ENR) BENZONATATE (UNII: 5P4DH56ENR) (BENZONATATE - UNIE5P4DH56ENR) BENZONATATE (UNII: 400 mg Index Section 2000 mg section 2000 m	Active Ingred	ient/Acti	ive Moie	ty							
Inactive Ingredients Ingredient Name			Ing	redient Name				Basis of	Streng	th Streng	
Ingredient NameStrengthBackage DescriptionStrengthIngredient NameStrengthglycerin (UNII: 2G6 (SP C2NHK)Strengthpropulparaben solution (UNII: CR6 (SP C2NHK)StrengthStrengthStrengthglycerin (UNII: CR6 (SP C2NHK)Strengthpropulparaben solution (UNII: CR6 (SP C2NHK))StrengthStrengthStoreStrengthStore <td col<="" td=""><td>BENZONATATE (</td><td>UNII: 5P4D</td><td>HS6ENR) (</td><td>BENZONATATE - UNII:</td><td>:5P4DHS6</td><td>SENR)</td><td></td><td>BENZONAT</td><td>ATE</td><td>100 mg</td></td>	<td>BENZONATATE (</td> <td>UNII: 5P4D</td> <td>HS6ENR) (</td> <td>BENZONATATE - UNII:</td> <td>:5P4DHS6</td> <td>SENR)</td> <td></td> <td>BENZONAT</td> <td>ATE</td> <td>100 mg</td>	BENZONATATE (UNII: 5P4D	HS6ENR) (BENZONATATE - UNII:	:5P4DHS6	SENR)		BENZONAT	ATE	100 mg
Ingredient NameStrengthBackage DescriptionStrengthIngredient NameStrengthglycerin (UNII: 2G6 (SP C2NHK)Strengthpropulparaben solution (UNII: CR6 (SP C2NHK)StrengthStrengthStrengthglycerin (UNII: CR6 (SP C2NHK)Strengthpropulparaben solution (UNII: CR6 (SP C2NHK))StrengthStrengthStoreStrengthStore <td col<="" th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td>	<th></th>										
D & C Yellow No. 10 (UNII: 35SUSUSQ3G) Image: State Sta	Inactive Ingre	dients									
g la tin (UNI: 2G86 QN327L) i g ly cerin (UNI: PD ⊂ A3C0 ⊂ X) i methylparaben sodium (UNI: CR6K9 C2NHK) i propylparaben sodium (UNI: 625NNB0G9N) socre propylparaben sodium (UNI: 625NNB0G9N) socre <t< td=""><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td>Strength</td></t<>				-						Strength	
igiycerin (UNII: PDC6A3CU × vertex (UNII: PDC6A3CU × vertex vert				G)							
methylparaben sodium (UNE: CR6K9C2NHK) = Second A second		- ,									
propylparaben solue: (UNII: 625NNB0G9N) → Product Characteristics Color yellow solution Capsules) Score no score → pe OVAL (Soft Gelatin Capsules) Size 9mm Flavor OVAL (Soft Gelatin Capsules) A1 Flavor A1 Name solution Score Size Size Size Size Size Size Size Siz											
Yoluct Characteristics Score no score Shape OVAL (Soft Gelatin Capsules) Size 9mm Imprint Code A1 Contains Size											
Image: Problem of the second secon	propylparaben so	dium (UN	II: 625NNB	0G9N)							
Image: Problem of the second secon											
Normal Sector Size 9mm Size	Product Chara	acteristi	cs								
Flavor Imprint Code A1 Contains Secondary Secondary Secondary Flavor Secondary Secondary Secondary Flavor Secondary Secondary Secondary Flavor Secondary Secondary Secondary Flavor Secondary Marketing Start Date Marketing End Date	Color	yello w					Score			no score	
Contains Image: Contains Packaging # Item Code Package Description Marketing Start Date	Shape	OVAL	OVAL (Soft Gelatin Capsules) Size				9 mm				
Packaging # Item Code Package Description Marketing Start Date Marketing End Date	Flavor	Imprint Code					A1				
# Item Code Package Description Marketing Start Date Marketing End Date	Contains										
# Item Code Package Description Marketing Start Date Marketing End Date											
	Packaging										
1 NDC:67296-0567-1 15 in 1 BOTTLE	# Item Co	de	Pack	age Description	M	arketing	Start Dat	e]	Marketi	ing End Date	
	NDC:67296-056	7-1	15 in 1 BO	TTLE							

Marketing Information					
application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
DA040682	0 1/13/20 10				
Ŋ	pplication Number or Monograph Citation	pplication Number or Monograph Citation Marketing Start Date			

Labeler - RedPharm Drug Inc. (008039641)

Establishment

Name	Address	ID/FEI	Business Operations
Swiss Caps AG		481784895	MANUFACTURE

Establishment

Name	Address	ID/FEI	Business Operations
Amneal Pharmaceuticals		831227801	LABEL, PACK, analysis

Revised: 7/2011

RedPharm Drug Inc.